Statistical and practical considerations in designing of immuno-oncology trials

Area of Science:

• Oncology
• Biostatistics
• Clinical Trial Design

Background:

• Immunotherapy's novel mechanisms present unique clinical trial design challenges.
• Delayed treatment effects are common with immunotherapies and impact trial power.
• Traditional sample size calculations may be inadequate without accounting for treatment delays.

Purpose of the Study:

• To develop an analytical approach for sample size computation in clinical trials with delayed treatment effects.
• To ensure adequate statistical power and accurate assessment of treatment benefit in immunotherapy trials.
• To provide guidance on designing interim analyses to avoid premature termination of effective treatments.

Main Methods:

• Utilizing a piece-wise proportional hazards model for sample size calculation.
• Analyzing the overall hazard ratio (HR) as a measure of average treatment benefit.
• Investigating the impact of delayed effects on statistical power and interim analyses.
• Employing the weighted log-rank test with Fleming-Harrington weights for supportive analysis.

Main Results:

• Failing to account for treatment delays can lead to significant power loss.
• The overall hazard ratio remains a meaningful measure of average patient benefit.
• Special considerations are needed for futility interim analyses to prevent premature stopping.
• Weighted log-rank tests can better reflect delayed effects and long-term benefits.

Conclusions:

• Accurate sample size calculation is crucial for immunotherapy trials with delayed effects.
• A piece-wise proportional hazards model offers a robust analytical approach.
• Careful design of interim analyses is necessary to preserve trial integrity.
• Supportive analyses can enhance the interpretation of treatment efficacy in the presence of delayed effects.